Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, Vives S, Serrano J, Bernal T, Martínez-Sánchez P, Tormo M, Rodríguez-Medina C, Herrera-Puente P, Lavilla-Rubira E, Boluda B, Acuña-Cruz E, Cano I, Cáceres S, Ballesteros J, Falantes J, Martínez-Cuadrón D, Pérez-Simón JA, Montesinos P; PETHEMA Group. Rodríguez-Arbolí E, et al. Among authors: bernal t. Cancer. 2024 Oct 30. doi: 10.1002/cncr.35618. Online ahead of print. Cancer. 2024. PMID: 39476204
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.
Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, Diaz-Beya M, Hermosin L, Maluquer C, Gonzalez-Campos J, Bernal T, Arriaga MS, Zamora L, Pratcorona M, Martino R, Larrayoz MJ, Artola T, Torrent A, Vall-Llovera F, Tormo M, Gil C, Novo A, Martinez-Sanchez P, Ribera J, Queipo MP, Gonzalez-Martinez T, Cabrero M, Cladera A, Cervera J, Orfao A, Ribera JM, Genesca E. Gonzalez-Gil C, et al. Among authors: bernal t. Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285416. Online ahead of print. Haematologica. 2024. PMID: 39113657 Free article.
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.
Crisà E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymäki M, Jädersten M, Komrokji R, Platzbecker U, Haase D, Hofmann WK, Al Ali NH, Barraco D, Bargay JJ, Bernal T, López Cadenas F, Calvisi A, Capodanno I, Cerrano M, Ciancia R, Crugnola M, Kündgen A, Finelli C, Fozza C, Frairia C, Freja E, Ganster C, Kubasch AS, Jimenez MJ, Latagliata R, Hernandez Mohedo F, Molero A, Vara Pampliega M, Perez CA, Pietrantuono G, Poloni A, Pomares H, Recasens V, Rüfer A, Signori A, Hellstrom-Lindberg E, Fenaux P, Sanz G, Santini V. Crisà E, et al. Among authors: bernal t. Leukemia. 2024 Oct;38(10):2259-2265. doi: 10.1038/s41375-024-02360-1. Epub 2024 Aug 5. Leukemia. 2024. PMID: 39103678
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.
Díez-Campelo M, López-Cadenas F, Xicoy B, Lumbreras E, González T, Del Rey González M, Sánchez-García J, Coll Jordà R, Slama B, Hernández-Rivas JÁ, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Götze KS, Arar A, Toribio S, Del Cañizo C, Hernández-Rivas JM, Fenaux P. Díez-Campelo M, et al. Among authors: bernal t. Lancet Haematol. 2024 Sep;11(9):e659-e670. doi: 10.1016/S2352-3026(24)00142-X. Epub 2024 Jul 18. Lancet Haematol. 2024. PMID: 39033767 Clinical Trial.
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador J, Martínez-Cuadrón D, Boluda B, Serrano J, Gil C, Pérez-Simón JA, Bernal T, Bergua JM, Martínez-López J, Rodríguez-Medina C, Vidriales MB, García-Boyero R, Algarra L, Polo M, Sayas MJ, Tormo M, Alonso-Domínguez JM, Herrera P, Lavilla E, Ramos F, Amigo ML, Vives-Polo S, Rodríguez-Macías G, Mena-Durán A, Pérez-Encinas MM, Arce-Fernández O, Cuello R, Sánchez-García J, Gómez-Casares MT, Chillón MC, Calasanz MJ, Ayala R, Rodriguez-Veiga R, Barragán E, Montesinos P; PETHEMA Group. Labrador J, et al. Among authors: bernal t. Cancer. 2024 Oct 15;130(20):3436-3451. doi: 10.1002/cncr.35431. Epub 2024 Jun 19. Cancer. 2024. PMID: 38896056
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU, Boluda B, Lavilla E, Tormo M, Botella C, Gil C, Vives S, Rodríguez C, Serrano J, Sayas MJ, Martínez-Sánchez P, Ramos F, Bernal T, Algarra L, Bergua-Burgues JM, Pérez-Simón JA, Herrera P, Barrios M, Noriega-Concepción V, Raposo-Puglia JA, Ayala R, Barragán E, Martínez-Cuadrón D, Amigo ML, López-Lorenzo JL, Lázaro-García A, Guimaraes JE, Colorado M, García-Boyero R, De Rueda-Ciller B, Foncillas-García M, Hong A, Labrador J, Alonso-Dominguez JM, Montesinos P; PETHEMA group. Suárez EU, et al. Among authors: bernal t. Ann Hematol. 2024 Aug;103(8):2845-2851. doi: 10.1007/s00277-024-05840-7. Epub 2024 Jun 17. Ann Hematol. 2024. PMID: 38884787
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C, Ayala R, Bilbao-Sieyro C, Chillón MC, Larráyoz MJ, Soria E, Aparicio-Pérez C, Bergua JM, Bernal T, Gil C, Tormo M, Algarra L, Alonso-Domínguez JM, Rodriguez-Arbolí E, Martínez-Sanchez P, Oliva A, Colorado-Araujo AM, Rodríguez-Medina C, Vives S, Hermosín L, Martínez-López J, García-Sanz R, Pérez-Simón JA, Calasanz MJ, Gómez-Casares MT, Barragán E, Sánchez-García J J, Montesinos P. De la Torre EP, et al. Among authors: bernal t. Haematologica. 2024 Aug 1;109(8):2682-2687. doi: 10.3324/haematol.2023.284601. Haematologica. 2024. PMID: 38634126 Free PMC article. No abstract available.
Author Correction: Study of the intestinal microbiota composition and the effect of treatment with intensive chemotherapy in patients recovered from acute leukemia.
Vázquez X, Lumbreras-Iglesias P, Rodicio MR, Fernández J, Bernal T, Moreno AF, de Ugarriza PL, Fernández-Verdugo A, Margolles A, Sabater C. Vázquez X, et al. Among authors: bernal t. Sci Rep. 2024 Apr 3;14(1):7860. doi: 10.1038/s41598-024-58097-5. Sci Rep. 2024. PMID: 38570572 Free PMC article. No abstract available.
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero JC, Dávila J, López-Pavía M, Such E, Bernal T, Ramos F, Calabuig M, Hernández Sánchez JM, Pomares H, Sánchez Barba M, Abáigar M, González B, Merchán B, Sancho-Tello R, Callejas M, Muñoz-Novas C, Cerveró C, Sanz G, Hernández Rivas JM, Díez Campelo M. Caballero JC, et al. Among authors: bernal t. Ther Adv Hematol. 2024 Jan 4;15:20406207231218157. doi: 10.1177/20406207231218157. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38186638 Free PMC article.
114 results